Clinical Trial Update: A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety and anti-tumor activity of NK cell therapy SNK01 in combination with chemotherapy or chemotherapy plus cetuximab for locally a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Chemotherapy (chemotherapy)
• SNK01

Snippet

Sponsor: NKMAX Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN